Visits: 4550, Avg visit time (secs): 201,71 Back to Index
| Page | Hits | Percent |
|---|---|---|
| 1434 | 31,52% | |
| /recipients.html | 1073 | 23,58% |
| /efsd-jdrf-novo/efsd-jdrf-novo-t1-recipients.html | 338 | 7,43% |
| /gsk/efsd-gsk-recipients.html | 204 | 4,48% |
| /msd/efsd-msd-recipients.html | 100 | 2,20% |
| /lilly/efsd-lilly-mh-recipients.html | 94 | 2,07% |
| /lilly/efsd-cds-lilly-recipients.html | 84 | 1,85% |
| /cr grant/efsd-clinres-recipients.html | 79 | 1,74% |
| /amylin/efsd-amylin-recipients.html | 57 | 1,25% |
| /lilly/efsd-lilly-recipients.html | 38 | 0,84% |
| /lifescan/efsd-lifescan-recipients.html | 37 | 0,81% |
| Page | Hits | Percent |
|---|---|---|
| /exit.htm | 1718 | 37,76% |
| /msd/efsd-msd-recipients.html | 425 | 9,34% |
| /programmes.html | 243 | 5,34% |
| /efsd-jdrf-novo/efsd-jdrf-novo-t1-recipients.html | 139 | 3,05% |
| /home.html | 135 | 2,97% |
| /reports.html | 124 | 2,73% |
| /novo-clinical-t2/efsd-novo-clin-t2-recipients.html | 112 | 2,46% |
| /gsk/efsd-gsk-recipients.html | 104 | 2,29% |
| /lilly/efsd-lilly-mh-recipients.html | 98 | 2,15% |
| /reviewers.html | 73 | 1,60% |
| /amylin/efsd-amylin-recipients.html | 63 | 1,38% |